Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
Inogen, Inc.NASDAQ: INGN
Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026
Deferred tax liabilities falls 11.3% from a year ago
Deferred tax liabilities stood at $6.57M at the end of Q1 FY2026, down 11.3% from a year earlier and down 2.6% from the prior quarter.
Context
- Deferred tax liabilities amounted to 2.3% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Deferred tax liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether deferred tax liabilities keeps falling in the next quarterly balance sheet after a -11.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.75M USD
- Year-over-year change
- -2.9%
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.75M | -2.9% |
| FY2024 | 2024-12-31 | 6.95M | -18.6% |
| FY2023 | 2023-12-31 | 8.54M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Tax Liabilities vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's Mar 2026 deferred tax liabilities of $6.57M is the highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -11.3% is the highest of 3, against a peer median of -54.2%.
- Deferred tax liabilities amounts to 2.3% of total assets for INGN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.57M | -11.3% | — | 2.3% | |
| Mar 2026 | $1.7M | -31.8% | — | 0.4% | |
| Dec 2025 | $600K | -76.7% | -43.5% | 0.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | -4.3% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INGN) | $0 | -54.2% | -23.9% | 0.0% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 235.52M | 187.01M | 125.49M | 113.8M | 103.73M |
| Short-term Investments | 9.99M | 0 | 2.98M | 0 | 15.85M |
| Net Receivables | 25.8M | 64.35M | 42.91M | 30.1M | 38.86M |
| Inventory | 31.87M | 34.09M | 21.84M | 24.81M | 25.97M |
| Other Current Assets | 0 | 19.19M | 13.85M | 16.74M | 13.89M |
| Total Current Assets | 329.19M | 304.65M | 207.07M | 185.45M | 198.3M |
| Property, Plant & Equipment (Net) | 63.84M | 64.92M | 70.65M | 62.7M | 52.86M |
| Goodwill | 32.98M | 32.85M | 10.06M | 9.47M | 10.7M |
| Intangible Assets | 60.15M | 177K | 34.59M | 30.49M | 30.76M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.36M | 2.45M | 3.83M | 8.08M | 6M |
| Total Non-current Assets | 160.33M | 100.4M | 119.13M | 110.73M | 100.33M |
| Total Assets | 489.51M | 405.04M | 326.19M | 296.19M | 298.63M |
| Account Payables | 10.26M | 18.24M | 13.45M | 16.62M | 20.26M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 561K | 492K | 27K | 142K | 183K |
| Deferred Revenue | 8.57M | 8.88M | 7.98M | 6.65M | 5.5M |
| Other Current Liabilities | 6.48M | 7.79M | 19.63M | 22.74M | 10.12M |
| Total Current Liabilities | 61.51M | 65.35M | 72.5M | 76.69M | 63.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 8.54M | 6.95M | 6.75M |
| Deferred Revenue (Non-current) | 11.86M | 10.4M | 8.23M | 5.75M | 3.6M |
| Other Non-current Liabilities | 22.63M | 12.12M | 13.85M | 16.35M | 18.19M |
| Total Non-current Liabilities | 57.77M | 42.29M | 48.89M | 45.64M | 42.86M |
| Total Liabilities | 119.29M | 107.64M | 121.38M | 122.33M | 106.39M |
| Common Stock | 23K | 23K | 23K | 24K | 27K |
| Retained Earnings | 69.27M | (14.5M) | (116.95M) | (152.84M) | (175.58M) |
| Accumulated OCI | 1.47M | (243K) | 1.23M | (1.5M) | 4.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 370.23M | 297.41M | 204.81M | 173.86M | 192.23M |
| Total Debt | 26.67M | 23.28M | 21.92M | 19.41M | 17.48M |
| Net Debt | (208.85M) | (163.74M) | (103.57M) | (94.39M) | (86.25M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.